<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144590">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01877785</url>
  </required_header>
  <id_info>
    <org_study_id>GV28916</org_study_id>
    <nct_id>NCT01877785</nct_id>
  </id_info>
  <brief_title>A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAA4549A in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, single-ascending dose study w ill assess
      the safety, tolerability and pharmacokinetics of ascending doses of M HAA4549A in healthy
      volunteers. Volunteers will be randomized to receive a singl e dose of MHAA4549A or matching
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Serum concentration-time profile of MHAA4549A</measure>
    <time_frame>Pre-dose on day 1 to day 120 post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>MHAA4549A Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHAA4549A</intervention_name>
    <description>Single-ascending dose of MHAA4549A</description>
    <arm_group_label>MHAA4549A Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to MHAA4549A</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Body mass index (BMI) between 18 and 32 kg/m2, inclusive

          -  Weight 40 to 100 kg

          -  In good health, determined by no clinically significant findings from medical
             history, 12-lead ECG, and vital signs

          -  Clinical laboratory evaluations should be within the reference range for the test
             laboratory unless deemed not clinically significant by the investigator and Sponsor

          -  Volunteers agree to use acceptable contraceptive measures

        Exclusion Criteria:

          -  History or clinically significant manifestations of disorders

          -  History of anaphylaxis, hypersensitivity or drug allergies

          -  History or presence of an abnormal ECG

          -  History of significant alcohol abuse within 1 year prior to screening or regular use
             of alcohol within 6 months prior to the screening visit

          -  History of significant drug abuse within 1 year prior to screening

          -  Current tobacco smokers

          -  Positive drug screen at screening or at check-in

          -  Positive pregnancy test result at screening or Day -1 or breast feeding during the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
